Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Division of Reproductive Endocrinology and Infertility, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Clin Obes. 2022 Dec;12(6):e12559. doi: 10.1111/cob.12559. Epub 2022 Sep 30.
Anti-Müllerian hormone (AMH) is commonly used as a proxy for ovarian reserve due to its secretion by antral follicles. It is considered a metric for prediction of ovarian response to certain assisted reproduction therapies. As obesity has a negative impact on fertility, it is important to establish whether obesity-induced hormonal changes influence AMH levels, if and how weight loss affects AMH, and if that influence represents altered reproductive function. The aim of this study was to review the existing literature on the effects of body mass index and weight loss on AMH levels. A PubMed literature keyword search with relevant terms was performed to identify studies that have reported on the AMH/BMI relationship in cohorts with or without polycystic ovarian syndrome (PCOS). A second search was performed to gather publications on weight loss and AMH. Both searches were filtered for all full-text, English-language, adult-female and human-only literature through 1 January 2022. The relationship between AMH and body mass index (BMI) in reproductive-aged women remains inconclusive, with studies in women with and without PCOS producing mixed results. Research in this area is currently limited by failure to analyse the full spectrum of obesity, hindering generalization to a global population increasingly affected by the condition. Some authors pointed to evidence of race/ethnicity as a confounding factor of the relationship, but results between studies are contradictory. Limited evidence on weight loss suggests it may decrease AMH levels despite improving fertility outcomes, particularly after bariatric surgery. The impact of BMI and weight loss on AMH levels has not been conclusively established. Future studies will require appropriate design and sample size calculations, consideration for additional potential confounding factors and inclusion of higher BMIs and a thorough analysis of the full range of obesity.
抗苗勒管激素 (AMH) 通常被用作卵巢储备的替代物,因为它由窦卵泡分泌。它被认为是预测某些辅助生殖治疗对卵巢反应的指标。由于肥胖对生育能力有负面影响,因此需要确定肥胖引起的激素变化是否会影响 AMH 水平、减肥是否会影响 AMH 以及这种影响是否代表生殖功能改变。本研究旨在回顾关于体重指数和减肥对 AMH 水平影响的现有文献。使用相关术语对 PubMed 文献关键词进行搜索,以确定报告了 AMH/BMI 关系的队列研究,这些队列研究有无多囊卵巢综合征 (PCOS)。进行了第二次搜索,以收集关于减肥和 AMH 的出版物。两次搜索都通过 2022 年 1 月 1 日过滤掉所有全文、英语、成年女性和仅限人类的文献。在生殖期妇女中,AMH 与体重指数 (BMI) 的关系仍不确定,有 PCOS 和无 PCOS 的妇女的研究结果不一。该领域的研究目前受到限制,无法分析肥胖的全貌,这阻碍了将其推广到越来越多受该疾病影响的全球人群。一些作者指出种族/民族是这种关系的混杂因素的证据,但研究结果相互矛盾。关于减肥的有限证据表明,尽管改善了生育结果,但它可能会降低 AMH 水平,尤其是在接受减肥手术后。BMI 和减肥对 AMH 水平的影响尚未得到明确证实。未来的研究需要适当的设计和样本量计算、考虑其他潜在的混杂因素,并纳入更高的 BMI 和对肥胖全貌的彻底分析。